Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy.

MLA

Remington, Benjamin C., et al. “Estimated Risk Reduction to Packaged Food Reactions by Epicutaneous Immunotherapy (EPIT) for Peanut Allergy.” Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, vol. 123, no. 5, Nov. 2019, p. 488. EBSCOhost, https://doi.org/10.1016/j.anai.2019.08.007.

APA

Remington, B. C., Krone, T., Kim, E. H., Bird, J. A., Green, T. D., Lack, G., Fleischer, D. M., & Koppelman, S. J. (2019). Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 123(5), 488. https://doi.org/10.1016/j.anai.2019.08.007

Chicago

Remington, Benjamin C, Tanja Krone, Edwin H Kim, J Andrew Bird, Todd D Green, Gideon Lack, David M Fleischer, and Stef J Koppelman. 2019. “Estimated Risk Reduction to Packaged Food Reactions by Epicutaneous Immunotherapy (EPIT) for Peanut Allergy.” Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology 123 (5): 488. doi:10.1016/j.anai.2019.08.007.